| Name | Title | Contact Details |
|---|
Twin Cities Public Television is a Saint Paul, MN-based company in the Business Services sector.
source1personnel is a Lawrence Township, NJ-based company in the Business Services sector.
MVESC is a nationally accredited regional resource center for schools in Coshocton, Hocking, Morgan, Muskingum, Noble and Perry counties. Covering more than 2,700 square miles, our agency has the largest service region in Ohio, making us a little bigger than the state of Rhode Island and almost as large as Delaware. We serve more than 2,000 teachers in 18 school districts, as well as more than 30,000 students. Within and beyond our seven counties, we have partnered with more than 105 educational service providers in 62 Ohio counties, 39 states and Canada. Our Mission We make connections to create services that contribute to learning. Our Vision We exist to serve in ways that help young people learn. To truly be the finest service center, our service work must be dependable, responsive and thoughtful. We serve by staying connected to our customers. We stay connected by valuing the relationships that have been built and maintained throughout the years. We must have both if we are to contribute to helping young people learn. We must create services that support learning.
Central Surveys Inc is a Shenandoah, IA-based company in the Business Services sector.
Cellerant Therapeutics is a clinical stage biotechnology company focused on developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant`s programs include: CLT-008, an off-the-shelf cellular immunotherapy, under evaluation in a multicenter, open-label, randomized, controlled Phase 2 clinical trial in patients with de novo AML; CSC030-ADC, a preclinical monoclonal antibody drug conjugate that selectively targets and kills leukemic stem and blast cells responsible for initiating and maintaining disease; and CSC012, a preclinical monoclonal antibody targeting leukemic and pre-leukemic stem cells for acute leukemias and myelodysplastic syndromes. The Company is also developing next generation CAR product candidates leveraging its proprietary immunocellular therapy and antibody discovery and development platform.